Latest Insider Transactions at Immuno Gen, Inc. (IMGN)
This section provides a real-time view of insider transactions for Immuno Gen, Inc. (IMGN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ImmunoGen, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ImmunoGen, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
2,645
+3.12%
|
$7,935
$3.83 P/Share
|
|
Jun 30
2022
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,509
+12.06%
|
$7,527
$3.83 P/Share
|
|
Jun 30
2022
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,342
+0.76%
|
$10,026
$3.83 P/Share
|
|
Jun 30
2022
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,342
+31.8%
|
$10,026
$3.83 P/Share
|
|
Dec 31
2021
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,957
+11.03%
|
$9,785
$5.6 P/Share
|
|
Dec 31
2021
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,496
+28.11%
|
$7,480
$5.6 P/Share
|
|
Dec 31
2021
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
2,051
+2.51%
|
$10,255
$5.6 P/Share
|
|
Dec 31
2021
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,761
+1.62%
|
$8,805
$5.6 P/Share
|
|
Sep 03
2021
|
Dean J Mitchell Director |
BUY
Exercise of conversion of derivative security
|
Direct |
83,000
+29.51%
|
$249,000
$3.29 P/Share
|
|
Jun 30
2021
|
Renee Lentini VP & PRIN ACCTG OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,683
+10.85%
|
$8,415
$5.52 P/Share
|
|
Jun 30
2021
|
Thomas Ryll SVP, Technical Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,849
+4.35%
|
$19,245
$5.52 P/Share
|
|
Jun 30
2021
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
1,768
+2.23%
|
$8,840
$5.52 P/Share
|
|
Jun 30
2021
|
Stacy Ann Coen SVP & CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,330
+50.0%
|
$11,650
$5.52 P/Share
|
|
Jun 30
2021
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,849
+0.88%
|
$19,245
$5.52 P/Share
|
|
Jun 30
2021
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,062
+1.92%
|
$10,310
$5.52 P/Share
|
|
Dec 31
2020
|
Anna Berkenblit SVP & CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
2,203
+2.09%
|
$8,812
$4.04 P/Share
|
|
Dec 31
2020
|
David G Foster V.P.-Fin., Prin. Acctg. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
362
+0.94%
|
$1,448
$4.04 P/Share
|
|
Dec 31
2020
|
Theresa Wingrove SVP OF REGULATORY AFFAIRS |
BUY
Grant, award, or other acquisition
|
Direct |
2,659
+3.39%
|
$10,636
$4.04 P/Share
|
|
Dec 31
2020
|
David G Foster V.P.-Fin., Prin. Acctg. Off. |
SELL
Open market or private sale
|
Direct |
11,052
-22.57%
|
$66,312
$6.38 P/Share
|
|
Dec 31
2020
|
David G Foster V.P.-Fin., Prin. Acctg. Off. |
BUY
Exercise of conversion of derivative security
|
Direct |
27,240
+35.75%
|
-
|
|
Dec 22
2020
|
Mark J Enyedy CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
10,000
-2.28%
|
-
|